Age-associated alterations in the immune system, also known as immunosenescence, can lead to a progressive loss of the immune system's ability to respond and develop immunity against diseases, leading to reduced vaccine responses in elderly people. TRON gGmbH largely contributed to the pioneering work in individualised RNA-based vaccination against cancer, as well as infectious diseases, and now aims to enhance vaccine effectiveness in the elderly.
Coming from the field of innate immune responses (optimising NK cell-mediated graft-versus-leukaemia effects and therapies), Ayline Kübler focuses on RNA-based immunotherapies to improve innate, as well as adaptive, immune responses.
In order to understand and improve immunotherapy outcomes for elderly people, we make use of mouse models of ageing and frailty and combine diverse RNA-based vaccination strategies and combination therapies with state-of-the-art immunological analysis techniques available at TRON gGmbH.
- Since 2019: Head of Animal Models and Imaging, Immunotherapy Development Center, TRON gGmbH, Mainz, Germany
- 2017 - 2019: Postdoctoral Scientist, Vaccines and Cellular Immunotherapy, Immunotherapy Development Center gGmbH, Mainz, Germany
- 2015 - 2017: Postdoctoral scientist and fortune junior project leader, Department of Hematology and Oncology, University Children’s Hospital, Tübingen, Germany
- 2011 - 2015: Scientist, Cellular Immunotherapy group, University Children’s Hospital, Tübingen, Germany
- Before 2011: Research assistant positions, Interfaculty Institute of Biochemistry, University of Tübingen, Germany & Cellular Immunotherapy group, University Children’s Hospital, Tübingen, Germany
- 2015: PhD in Biochemistry (field of immuno-oncology), Eberhard Karls University, Tübingen, Germany
- 2011: Diploma in Biochemistry, Eberhard Karls University, Tübingen, Germany
Selected publications by Ayline Kübler
Kübler A, Woiterski J, Witte KE, Bühring HJ, Hartwig UF, Ebinger M, Oevermann L, Mezger M, Herr W, Lang P, Handgretinger R, Münz C and André MC (2014) Both mature KIR+ but also immature KIR- NK control pediatric acute B cell precursor leukemia NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice. Blood, 124:3914–3923 Link
Koerner SP, André MC, Leibold JS, Kousis PC, Kübler A, Pal M, Haen SP, Bühring HJ, Grosse-Hovest L, Jung G and Salih HR (2017) An Fc-optimized CD133 antibody for induction of NK cell reactivity against myeloid leukemia. Leukemia, 31:459–469 Link
Steinbacher J, Baltz-Ghahremanpour K, Schmiedel BJ, Steinle A, Jung G, Kübler A,André MC, Grosse-Hovest L and Salih HR (2015) An Fc-optimized NKG2D-IgG fusion protein for induction of natural killer cell reactivity against leukemia. Int J Cancer, 136:1073–1084 Link
Gille C, Orlikowsky TW, Spring B, Hartwig UF, Wilhelm A, Wirth A, Goecke B, Handgretinger R, Poets CF and André MC (2012) Monocytes derived from humanized neonatal NOD/SCID/IL2Rγ(null) mice are phenotypically immature and exhibit functional impairments. Hum Immunol, 73:346–354 Link
André MC, Erbacher A, Gille C, Schmauke V, Goecke B, Hohberger A, Mang P, Wilhelm A, Mueller I, Herr W, Lang P, Handgretinger R and Hartwig UF (2010) Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells. J Immunol, 185:2710–20 Link